Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial. The stock was up 15% to $2.50 after the market close on Wednesday.
Management expects 2024 fourth quarter revenue of approximately $3.0 million and full year 2024 of approximately $8.6 million, representing growth year-over-year of over 100% for the third consecutive ...
Management expects 2024 fourth quarter revenue of approximately $3.0 million and full year 2024 of approximately $8.6 million, representing growth year-over-year of over 100% for the third consecutive ...
GATC West Virginia played a role in a groundbreaking AI-powered analysis of a new liver cancer drug in development — an analysis that saved inestimable hours and dollars for the client. GATC West ...
Discover how Palantir is expanding its AI technology across government and commercial sectors, reducing its reliance on government contracts. Read my analysis here.